SMT201300078B - Nucleosidi di uracile spiroossietano - Google Patents

Nucleosidi di uracile spiroossietano

Info

Publication number
SMT201300078B
SMT201300078B SM201300078T SM201300078T SMT201300078B SM T201300078 B SMT201300078 B SM T201300078B SM 201300078 T SM201300078 T SM 201300078T SM 201300078 T SM201300078 T SM 201300078T SM T201300078 B SMT201300078 B SM T201300078B
Authority
SM
San Marino
Prior art keywords
spiroossietano
nucleosides
uracil
uracil spiroossietano
spiroossietano nucleosides
Prior art date
Application number
SM201300078T
Other languages
English (en)
Italian (it)
Inventor
Tim Hugo Maria Jonckers
Pierre Jean-Marie Bernard Raboisson
Koen Vandyck
Steven Maurice Paula Van Hoof
Lili Hu
Abdellag Tahri
Original Assignee
Janssen Products
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Products, Medivir Ab filed Critical Janssen Products
Publication of SMT201300078B publication Critical patent/SMT201300078B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/067Pyrimidine radicals with ribosyl as the saccharide radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/503Pyridazines; Hydrogenated pyridazines spiro-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02Acyclic radicals, not substituted by cyclic structures
    • C07H15/04Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18Acyclic radicals, substituted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SM201300078T 2009-05-14 2013-07-04 Nucleosidi di uracile spiroossietano SMT201300078B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160215 2009-05-14
PCT/EP2010/056438 WO2010130726A1 (en) 2009-05-14 2010-05-11 Uracyl spirooxetane nucleosides

Publications (1)

Publication Number Publication Date
SMT201300078B true SMT201300078B (it) 2013-09-06

Family

ID=40823307

Family Applications (2)

Application Number Title Priority Date Filing Date
SM201300078T SMT201300078B (it) 2009-05-14 2013-07-04 Nucleosidi di uracile spiroossietano
SM201400085T SMT201400085B (it) 2009-05-14 2014-06-30 Nucleosidi di uracile spiroosietano

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM201400085T SMT201400085B (it) 2009-05-14 2014-06-30 Nucleosidi di uracile spiroosietano

Country Status (39)

Country Link
US (2) US8481510B2 (me)
EP (2) EP2511282B1 (me)
JP (2) JP5778135B2 (me)
KR (1) KR101806837B1 (me)
CN (1) CN102439024B (me)
AP (1) AP2783A (me)
AR (1) AR076579A1 (me)
AU (1) AU2010247439B2 (me)
BR (1) BRPI1010579A2 (me)
CA (1) CA2760329C (me)
CL (1) CL2011002859A1 (me)
CO (1) CO6440533A2 (me)
CR (1) CR20120297A (me)
CY (2) CY1114081T1 (me)
DK (2) DK2511282T3 (me)
EA (1) EA022084B1 (me)
EC (1) ECSP11011461A (me)
ES (2) ES2477598T3 (me)
HK (1) HK1166326A1 (me)
HN (1) HN2011003014A (me)
HR (2) HRP20130554T1 (me)
IL (1) IL215955A (me)
JO (1) JO3027B1 (me)
ME (1) ME01478B (me)
MX (1) MX2011012027A (me)
MY (1) MY157018A (me)
NI (1) NI201100197A (me)
NZ (1) NZ596073A (me)
PL (2) PL2430035T3 (me)
PT (2) PT2430035E (me)
RS (1) RS52822B (me)
SG (1) SG175981A1 (me)
SI (2) SI2511282T1 (me)
SM (2) SMT201300078B (me)
TW (1) TWI461432B (me)
UA (1) UA105790C2 (me)
UY (1) UY32642A (me)
WO (1) WO2010130726A1 (me)
ZA (1) ZA201108309B (me)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2376515A1 (en) 2008-12-23 2011-10-19 Pharmasset, Inc. Synthesis of purine nucleosides
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
ES2605433T3 (es) * 2010-11-10 2017-03-14 Janssen Products, L.P. Fosforamidatos de espironucleósido oxetánico uracílico
ES2531583T3 (es) * 2010-11-10 2015-03-17 Janssen Products, L.P. Fosforamidatos de espironucleósido oxetánico uracílico
AU2015252113B2 (en) * 2010-11-30 2017-05-04 Gilead Pharmasset Llc Compounds
PT3042910T (pt) * 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
EP2697241B1 (en) * 2011-04-13 2019-06-12 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
MX2014014323A (es) 2012-05-25 2015-02-12 Janssen R & D Ireland Nucleosidos de espirooxetano de uracilo.
AU2014225052B2 (en) 2013-03-08 2016-11-10 Nanjing Sanhome Pharmaceutical Co., Ltd. Novel nucleoside phosphoramidate compound and use thereof
EP2984097B1 (en) 2013-04-12 2017-03-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
CN104231023B (zh) * 2013-06-06 2019-02-05 南京汇诚制药有限公司 三环稠杂环类核苷氨基磷酸酯化合物、其制备方法及应用
CA2928254A1 (en) * 2013-11-28 2015-06-04 Jennifer Albaneze-Walker Crystal form of nucleoside inhibitor of hcv
IL302877A (en) 2015-03-06 2023-07-01 Atea Pharmaceuticals Inc Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
SI3512863T1 (sl) 2016-09-07 2022-04-29 Atea Pharmaceuticals, Inc. 2'-substituirani-N6-substituirani purinski nukleotidi za zdravljenje virusa RNA
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
WO2019139920A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
MX2022012900A (es) * 2020-04-14 2023-01-24 Janssen Pharmaceuticals Inc Análogos de nucleósido espirocíclico para el tratamiento de la hepatitis e.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100828453B1 (ko) * 2001-01-22 2008-05-13 머크 앤드 캄파니 인코포레이티드 Rna 의존성 rna 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
WO2006012078A2 (en) * 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
AU2007215114A1 (en) 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان

Also Published As

Publication number Publication date
CY1115383T1 (el) 2017-01-04
MY157018A (en) 2016-04-15
MX2011012027A (es) 2012-02-28
TWI461432B (zh) 2014-11-21
SG175981A1 (en) 2011-12-29
IL215955A (en) 2015-03-31
DK2511282T3 (da) 2014-07-07
CO6440533A2 (es) 2012-05-15
ES2477598T3 (es) 2014-07-17
ME01478B (me) 2014-04-20
IL215955A0 (en) 2012-01-31
EP2511282B1 (en) 2014-04-02
AP2783A (en) 2013-10-31
CY1114081T1 (el) 2016-07-27
PT2430035E (pt) 2013-05-22
EP2430035A1 (en) 2012-03-21
CR20120297A (es) 2012-10-25
ECSP11011461A (es) 2012-02-29
CL2011002859A1 (es) 2012-07-20
JP2012526764A (ja) 2012-11-01
UY32642A (es) 2010-11-30
PL2430035T3 (pl) 2013-08-30
HRP20140605T1 (hr) 2014-09-26
EP2511282A1 (en) 2012-10-17
KR20120018355A (ko) 2012-03-02
SI2511282T1 (sl) 2014-09-30
JP5778135B2 (ja) 2015-09-16
US8481510B2 (en) 2013-07-09
ZA201108309B (en) 2013-04-24
CA2760329C (en) 2017-10-31
JP2015180692A (ja) 2015-10-15
US20130217648A1 (en) 2013-08-22
AU2010247439A1 (en) 2011-12-01
BRPI1010579A2 (pt) 2016-03-15
US20120065156A1 (en) 2012-03-15
AP2011005958A0 (en) 2011-10-31
EP2430035B1 (en) 2013-04-03
UA105790C2 (uk) 2014-06-25
PL2511282T3 (pl) 2014-09-30
EA201171406A1 (ru) 2012-05-30
RS52822B (en) 2013-10-31
AU2010247439B2 (en) 2014-09-25
TW201100442A (en) 2011-01-01
PT2511282E (pt) 2014-07-11
JO3027B1 (ar) 2016-09-05
EA022084B1 (ru) 2015-10-30
NI201100197A (es) 2012-05-28
CN102439024A (zh) 2012-05-02
CA2760329A1 (en) 2010-11-18
ES2411086T3 (es) 2013-07-04
NZ596073A (en) 2013-02-22
SMT201400085B (it) 2014-09-08
CN102439024B (zh) 2014-09-17
HRP20130554T1 (en) 2013-07-31
AR076579A1 (es) 2011-06-22
US8933052B2 (en) 2015-01-13
DK2430035T3 (da) 2013-05-27
HN2011003014A (es) 2014-06-30
HK1166326A1 (en) 2012-10-26
WO2010130726A1 (en) 2010-11-18
KR101806837B1 (ko) 2017-12-08
SI2430035T1 (sl) 2013-08-30

Similar Documents

Publication Publication Date Title
SMT201400085B (it) Nucleosidi di uracile spiroosietano
SMT201600351B (it) Composti antivirali
BR112012007122A2 (pt) derivados de fosforamidatos de nucleosídeos
BRPI0922681A2 (pt) nucleiotídeos de uracil ciclopropila
ZA201008829B (en) Nucleoside cyclicphosphates
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
DK2154967T3 (da) Pyrimidinderivater
ZA201106827B (en) Substituted nucleoside and nucleotide analogs
BRPI0922508A2 (pt) Análogos de nucleosídeo
BRPI0819797A2 (pt) compostos de nucleosídeos antivirais
BR112012005616A2 (pt) compostos antivirais heterocíclicos
BRPI1010852A2 (pt) compostos antivirais heterocíclicos
BRPI1013493A2 (pt) composto de pirimidina
BRPI1016266A2 (pt) compostos antivirais heterocíclicos
BRPI0811115A2 (pt) Compostos de heteroarilamida pirimidona
DK2373644T3 (da) Pyridazinonderivater
BRPI1010900A2 (pt) compostos antivirais heterocíclicos
BRPI0923903A2 (pt) Derivados de piridazinona
TH104960B (th) อนุพันธ์ซับสทิทิวเต็ดอะริลลาไมด์ออกซาเซพิโนไพริมิโดน
FI20090160A0 (fi) Avaruusalus
FR2942717B1 (fr) Nouvel agent antiviral
FIU20090270U0 (fi) Oligonukleotidikonjugaatteja
TH114434B (th) คาร์บอไฮเดรต
TH94206B (th) ปากกา
TH105865B (th) ปากกา